Takeda Pharmaceutical analyst ratings
Takeda Pharmaceutical analyst ratings
While ratings are subjective and will change, the latest Takeda Pharmaceutical (TAK) rating was a upgraded with a price target of $21.00 to $24.00. The current price Takeda Pharmaceutical (TAK) is trading at is $14.41, which is out of the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 07/19/2022 | 66.61% | Cowen & Co. | $21 → $24 | Upgrades | Market Perform → Outperform |
| 10/07/2021 | — | Morgan Stanley | Downgrades | Overweight → Equal-Weight | |
| 03/11/2020 | 108.26% | JP Morgan | $31 → $30 | Maintains | Overweight |
| 11/01/2019 | 35.37% | Cowen & Co. | → $19.5 | Initiates Coverage On | → Market Perform |
| 09/24/2019 | — | Jefferies | Initiates Coverage On | → Buy | |
| 03/19/2019 | — | Goldman Sachs | Reinstates | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 2022 年 7 月 19 日 | 66.61% | Cowen & Co. | 21 美元 → 24 美元 | 升级 | 市场表现 → 跑赢大盘 |
| 2021 年 7 月 10 日 | — | 摩根士丹利 | 降级 | 超重 → 重量相等 | |
| 03/11/2020 | 108.26% | 摩根大通 | 31 美元 → 30 美元 | 维护 | 超重 |
| 11/01/2019 | 35.37% | Cowen & Co. | → 19.5 美元 | 启动覆盖范围开启 | → 市场表现 |
| 2019 年 9 月 24 日 | — | 杰富瑞集团 | 启动覆盖范围开启 | → 购买 | |
| 03/19/2019 | — | 高盛 | 恢复 | → 购买 |
Takeda Pharmaceutical Questions & Answers
武田制药问答
The latest price target for Takeda Pharmaceutical (NYSE: TAK) was reported by Cowen & Co. on July 19, 2022. The analyst firm set a price target for $24.00 expecting TAK to rise to within 12 months (a possible 66.61% upside). 2 analyst firms have reported ratings in the last year.
Cowen & Co. 于2022年7月19日公布了武田制药（纽约证券交易所代码：TAK）的最新目标股价。该分析公司将目标股价定为24.00美元，预计TAK将在12个月内升至12个月内（可能上涨66.61％）。去年有两家分析公司公布了评级。
The latest analyst rating for Takeda Pharmaceutical (NYSE: TAK) was provided by Cowen & Co., and Takeda Pharmaceutical upgraded their outperform rating.
武田制药（纽约证券交易所代码：TAK）的最新分析师评级由Cowen & Co. 提供，武田药业上调了跑赢大盘的评级。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Takeda Pharmaceutical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Takeda Pharmaceutical was filed on July 19, 2022 so you should expect the next rating to be made available sometime around July 19, 2023.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与武田制药的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月做一次这样的评级，因此每家公司每年应该获得4次评级。武田制药的最新评级是在2022年7月19日发布的，因此您应该预计下一个评级将在2023年7月19日左右公布。
While ratings are subjective and will change, the latest Takeda Pharmaceutical (TAK) rating was a upgraded with a price target of $21.00 to $24.00. The current price Takeda Pharmaceutical (TAK) is trading at is $14.41, which is out of the analyst's predicted range.
尽管评级是主观的，并且会发生变化，但武田制药（TAK）的最新评级已上调，目标股价为21.00美元，至24.00美元。武田制药（TAK）目前的交易价格为14.41美元，超出了分析师的预期区间。
